¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21
±³À°ÀÏÀÚ : 2024-06-21
±³À°Àå¼Ò : ¼­¿ï·Ôµ¥È£ÅÚ

±³À°ÁÖÁ¦ : Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2

ÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486  

À̸ÞÀÏ : cancer2@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú, ¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈ­ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ

Âü¼®¿¹»óÀÎ : 1500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 17 ½Ã°£ 55ºÐ

¼¼ºÎ¼ö°­·á : 250,000¿ø  

ºñ°í "1. ȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 12¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 7¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 18¸¸¿ø, 2. ºñȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 18¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 7¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 25¸¸¿ø"


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 09:00~09:25 Preclinical study of biparatopic ADC targeting MET to overcome acquired resistance to EGFR TKI in EGFR-mutant NSCLC ÀÓ¼±¹Î(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 09:25~09:50 Next-generation antibody ±èÈ£¹Î(KAIST)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 09:50~10:15 Engineering next generation T cell therapy for cancer ±èÂùÇõ(¼­¿ï´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 10:15~10:40 The next generation CAR-T therapies landscape ¼­Çü¼®(¼­¿ï´ë ¾à´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 09:00~09:25 A system development methodology using protein 3D structure prediction in the field of biomedicine È«µ¿¿Ï(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 09:25~09:50 Machine leaning on cancer genome and immune data can predict chemotherapy response of upper GI cancers Hidewaki Nakagawa(RIKEN Center for Integrative Medical Sciences)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 09:50~10:15 AI using multiple clinical & imaging data for cancer research Á¤±Ôȯ(»ï¼ºÀ¶ÇÕÀÇ°úÇпø)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 10:15~10:40 AI development and real-world validation through medical imaging standardization À±¼øÈ£(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 09:00~09:25 Evolution of the WHO classifications of CNS tumors in the molecular era ±è¼¼ÈÆ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 09:25~09:50 Lymphoma ÀüÀ±°æ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 09:50~10:15 Breast tumors Puay Hoon Tan(Duke-NUS Medical School)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 10:15~10:40 Tumors of the gastrointestinal tracts ±è°æ¹Ì(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 09:00~09:20 A first-line treatment option for locally advanced unresectable or metastatic biliary track cancer õÀç°æ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 09:20~10:00 A journey to the hope of HR+/HER2- EBC&MBC patient: Abemaciclib new data ÀÌÁöÀº(°¡Å縯ÀÇ´ë)

ÈÞ½Ä 06¿ù 21ÀÏ 10:40~11:00 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 11:00~11:40 Evolution of cancer treatment and development of Korean Cancer Association ¹æ¿µÁÖ(¼­¿ïÀÇ´ë/¹æ¾Ø¿Á)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 11:40~12:20 How whole genome sequencing can advance precision medicine Emile Voest(Netherlands Cancer Institute)

ÈÞ½Ä 06¿ù 21ÀÏ 12:20~12:30 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 12:30~13:10 Unlocking the door: A paradigm shift in early-stage NSCLC treatment with pembrolizumab À̼¼ÈÆ(¼º±Õ°üÀÇ´ë)

ÈÞ½Ä 06¿ù 21ÀÏ 13:10~14:30 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 14:30~14:55 Whole-genome sequencing reveals the homologous recombination deficiency in human cancer ÁÖ¿µ¼®(KAIST)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 14:55~15:20 Metabolic triggers for cancer genome evolution Ashok Venkitaraman(National University of Singapore)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 15:20~15:45 In vivo CRISPR therapy targeting cancer-specific genetic alterations ±ÇÅÂÁØ(UNIST)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 15:45~16:10 Targeting DNA damage repair deficiency in gynaecological cancers David SP Tan(National University Cancer Institute)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 14:30~14:55 Role of vascular functions in cancer treatment ¼Ûâ¿ø(University of Minnesota)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 14:55~15:20 Vascular regulation of tumor immune exclusion and progression ±è¹Î¾Æ(Columbia University Medical Center)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal B 15:20~15:45 Hypoxia as a regulator of tumor stroma ÀÌ°æÀº(University of Michigan)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 14:30~14:55 Proteogenomic characterization reveals estrogen signaling as a target for never-smoker lung adenocarcinoma patients without EGFR or ALK alterations ±è¼±¿µ(Çѱ¹»ý¸í°øÇבּ¸¿ø)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 14:55~15:20 Emerging therapeutic targets for systemic treatment of advanced gastric cancer ±èÀÎÈ£(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 15:20~15:45 Single cell-based target identification in cancers ¹ÚÁöȯ(GIST)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 15:45~16:10 Dissecting heterogeneity of histologic patterns reveals a novel target of lung adenocarcinoma À̽ſ±(°æºÏÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 14:30~14:55 Pathology insights in MDT: Driving precision diagnostics and treatment in cancer care ÀÌÇý½Â(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 14:55~15:20 The vital importance of the multidisciplinary team win managing lung cancer: A thoracic surgeon¡¯s view ÀÌ⿵(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 15:20~15:45 Navigating the cancer journey: The integral role of medical oncology in MDT strategies ¹Ú¼¼ÈÆ(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire B 15:45~16:10 Targeting cancer with precision: The integral role of radiation oncology in MDT strategies À̼º¿í(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 14:30~14:45 ±¹°¡ ¾ÏÁø·á°¡À̵å¶óÀÎ »ç¾÷ ÃßÁø ÇöȲ °ûÈ£½Å(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 14:45~15:00 ¾ÏÁø·á°¡À̵å¶óÀÎ °³¹ß ¹æ¹ý·Ð°ú °Ë¼ö»çÇ× ±è¼ö¿µ(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 15:00~15:15 À§¾Ï Áø·á °¡À̵å¶óÀÎ ¼Ò°³ ÇÑÇý¼÷(ÃæºÏÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 15:15~15:30 °©»ó¼±¾Ï Áø·á °¡À̵å¶óÀÎ ¼Ò°³ ÀÌÀº°æ(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 06¿ù 21ÀÏ Belle-Vue 15:30~15:45 °áÀå¾Ï Áø·á °¡À̵å¶óÀÎ ¼Ò°³ °ûÁ¤¸é(°í·ÁÀÇ´ë)

Åä·Ð 06¿ù 21ÀÏ Belle-Vue 15:45~16:10 ÆгÎÅä·Ð ()

ÈÞ½Ä 06¿ù 21ÀÏ 16:10~16:30 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 16:30~16:50 Tumor informed vs. tumor agnostic ctDNA analysis À̽ÂÅÂ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 16:50~17:10 A new era of molecular residual disease: Optimizing perioperative chemotherapy for colorectal cancer Eiji Oki (Graduate School of Medical Sciences, Kyushu University)

±³À°½Ã°£ 06¿ù 21ÀÏ Crystal A 17:10~17:30 ctDNA monitoring in metastatic cancer ÃÖ¿ø¿µ(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 16:30~16:50 Mechanisms of oncogenic tyrosine kinase fusion selection in human cancer Á¤ÅÃÁø(Boston Children)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 16:50~17:10 A study on the immunological microenvironment of pancreatic cancer ±è´ö±â(Ãæ³²´ëº´¿ø)

±³À°½Ã°£ 06¿ù 21ÀÏ Sapphire A 17:10~17:30 Immunotherapy in pancreatic cancer: DNA damage repair deficiency & what else ¹Ú¿õ±â(Memorial Sloan Kettering Cancer Center)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22
´ÙÀ½±Û ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21135 °æ±â Á¦10Â÷ ¿¬¼¼ÀÇ´ë ¼Ò¾Æû¼Ò³â°ú Áö¿ªÀÇ»ç Áý´ãȸ : 2024-07-31 0 27 2024-06-19
21134 °æ±â 2024 Çѱ¹¼ö¸éÇÐȸ ÇÏ°èÇмú´ëȸ : 2024-07-26 0 47 2024-06-19
21133 ¼­¿ï 2024³â ´ëÇÑÇǺη¹ÀÌÀúÇÐȸ Á¦25ȸ Çмú´ëȸ : 2024-07-21 0 33 2024-06-19
21132 ¼­¿ï ´ëÇÑÀÓ»ó¾Ï´ë»çÀÇÇÐȸ 2024³â Ãß°èÇмú´ëȸ IVC¿Í Detox : 2024-07-21 0 27 2024-06-19
21131 ´ë±¸ ´ë±¸°æºÏ³»°úÇÐȸ 2024³â Á¤±âÇмú´ëȸ : 2024-07-21 0 26 2024-06-19
21130 Á¦ÁÖ Á¦13ȸ ´ëÇѳ»ºÐºñÇÐȸ Á¦ÁÖÁöȸ ¿¬¼ö°­Á : 2024-07-20 0 14 2024-06-19
21129 ±¤ÁÖ Á¦225Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ ±¤ÁÖÀü³²Áöȸ ¿¬¼ö°­Á : 2024-07-16 0 17 2024-06-19
21128 ºÎ»ê ´ëÇѳ»°úÀÇ»çȸ Á¦3ȸ ÃÊÀ½ÆÄ ½ÇÀü ¾ÆÄ«µ¥¹Ì : 2024-07-15 0 31 2024-06-19
21127 ¼­¿ï 2024 ¼¼ºê¶õ½ºº´¿ø ¼ÒÈ­±âÇÐ ¿¬¼ö°­Á : 2024-07-14 0 34 2024-06-19
21126 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑôÃß¿µ»óÀÇÇÐȸ Á¤±â¿¬¼ö°­Á : 2024-07-14 0 18 2024-06-19
21125 ¼­¿ï Á¦29Â÷ Ưº°¿¬¼ö°­Á – »êºÎÀΰú Áúȯ óġÀÇ ÃֽŠÁö°ß : 2024-07-14 0 24 2024-06-19
21124 °­¿ø 2024³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ °­¿øÁöȸ ¿¬¼ö°­Á : 2024-07-14 0 22 2024-06-19
21123 ¼­¿ï 2024³â ´ëÇѹ̼¼¼ö¼úÇÐȸ Ãá°è ¹Ì¼¼¼ö¼ú ¿öÅ©¼ó : 2024-07-14 0 20 2024-06-19
21122 ¼­¿ï Çѱ¹¹é³»Àå±¼Àý¼ö¼úÇÐȸ 2024 KSCRS Annual Symposium(2ÀÏÂ÷) : 2024-07-14 0 14 2024-06-19
21121 ¼­¿ï Á¦8ȸ ÀüÀÓÀÇ Àü°øÀÇ °³¿øÀǸ¦ À§ÇÑ °£Áúȯ ¿¬¼ö°­Á : 2024-07-14 0 28 2024-06-19
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷